- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
New At-Home Syphilis Test Has Potential to Save Lives and Money
CDC data from 2021 show the lifetime cost of treating syphilis to be $1190.
Syphilis is a serious bacterial infection caused by Treponema pallidum,1 and one of the most common sexually transmitted infections (STIs) in the US.2-4 It is both treatable and curable, but there is potential for serious downstream health outcomes. These include a higher risk of acquiring HIV and other STIs (eg, gonorrhea and chlamydia), organ damage, miscarriage, infant death, and heart and blood vessel complications.1,3,5,6
There are 4 types of syphilis: primary syphilis, secondary syphilis, latent syphilis, and congenital syphilis (mother-to-baby transmission through the placenta).1 The infection is typically spread through sexual contact.
The lifetime cost to treat a syphilis infection is $1190, according to 2021 data from the CDC.7 However, such an amount is out of reach for many. That combined with the recent significant surge in cases of syphilis—they are now at a 70-year high, with a nearly 80% jump in syphilis overall and a 183% leap in congenital syphilis over the 4-year period from 2018 to 20228—make the recent FDA approval of an at-home test that much more timely.9,10
On Friday, August 16, the FDA authorized the First To Know Syphilis Test from NOWDiagnostics. With just a finger prick to draw a few drops of blood, the at-home test available over the counter is able to detect T pallidum within 15 minutes—no prescription needed. Positive results must be confirmed with a health care provider and to inform treatment.9,10
The lifetime cost of treating a syphilis infection is estimated to be $1190, but access to testing is inadequate and unequal, particularly among vulnerable populations | Image Credit: stock.adobe.com
At a price tag of $29.98, acquiring the test is achievable; however, health insurance coverage of the test is not always a guarantee,11 with such considerations as gender, risk factors, and pregnancy status having an impact on coverage of specific STI tests.12 Other tests for syphilis are approved, but only health care providers can do them.13
With the ability of a syphilis infection to go undetected for years, this new testing route also has potential to head off the downstream health care costs mentioned above and increase access to equitable care for STI testing.
In a news release announcing the authorization, Rob Weigle, CEO of NOWDiagnostics, said, "Testing is one of the most important tools we have in preventing the spread of sexually transmitted infections, and for the first time ever, consumers now have a fast and simple syphilis test that can be performed in the privacy of one’s home, with a result in minutes.”14
To boost uptake, the company hopes to collaborate with federal agencies, state health officials, local health officials, and major retailers to provide the test for free. There are also plans to reach more vulnerable populations—those affected by social determinants of health such as housing instability and lack of adequate health care—through social media and targeted advertising.9
The primary treatment for syphilis is penicillin, but one form of this antibiotic from Pfizer has been in short supply for well over a year. When first announced, the pharma giant had hoped to see an uptick in inventory by the second half of 2024,15 but this deadline has now been pushed back to the fourth quarter of this year.9
Experts attribute the surge in syphilis cases to 3 primary causes9:
- Inadequate screening coverage
- Lack of funding at federal and local levels
- How COVID-19 affected STI clinic operation
The marketing authorization came down under the FDA’s de novo premarket review pathway and incorporated data from a clinical study of 1270 individuals who found the test easy to use. In addition, this trial demonstrated a 99.5% accuracy rate when identifying blood specimens that were negative for syphilis and a 93.4% accuracy rate for specimens that were positive for syphilis compared with 3 FDA lab-based tests.
Market availability, online and in brick-and-mortar stores, is predicted to be as early as September.9
References
1. Syphilis. World Health Organization. May 21, 2024. Accessed August 19, 2024. https://www.who.int/news-room/fact-sheets/detail/syphilis#:~:text=Without%20treatment%2C%20the%20tertiary%20phase,syphilis%20can%20also%20cause%20death
2. Murtha J. 8 common STDs: what you need to know. Pfizer. Accessed August 19, 2024. https://www.pfizer.com/news/articles/8_common_stds
3. Most common STDs for women and men. WebMD. March 3, 2024. Accessed August 19, 2024. https://www.webmd.com/sexual-conditions/most-common-stds-men-women
4. National overview of STIs, 2022. CDC. Updated January 30, 2024. Accessed August 19, 2024. https://www.cdc.gov/std/statistics/2022/overview.htm
5. Nelson R. Syphilis rates soar in the USA amid penicillin shortage. Lancet. 2023;402(10401):515. doi:10.1016/S0140-6736(23)01665-3
6. Syphilis. Mayo Clinic. July 20, 2024. Accessed August 19, 2024. https://www.mayoclinic.org/diseases-conditions/syphilis/symptoms-causes/syc-20351756
7. Chesson HW, Peterman TA. The estimated lifetime medical cost of syphilis in the United States. Sex Transm Dis. 2021;48(4):253-259. doi:10.1097/OLQ.0000000000001353
8. Sexually transmitted infections. CDC. Accessed August 19, 2024. https://www.cdc.gov/std/statistics/2022/default.htm#:~:text=In%202022%2C%20more%20than%202.5,from%20all%20STI%20prevention%20partners
9. Roubein R. FDA clears first at-home syphilis test amid surge in cases. Washington Post. August 16, 2024. Accessed August 19, 2024. https://www.washingtonpost.com/health/2024/08/16/syphilis-test-at-home/
10. FDA marketing authorization enables increased access to first step of syphilis diagnosis. News release. FDA; August 16, 2024. Accessed August 19, 2024. https://www.fda.gov/news-events/press-announcements/fda-marketing-authorization-enables-increased-access-first-step-syphilis-diagnosis
11. Jordan E. STD testing without insurance. Exposed. September 27, 2022. Accessed August 19, 2024. https://www.stdcheck.com/blog/std-testing-insurance/
12. Does health insurance cover sexual health services? Planned Parenthood. Accessed August 19, 2024. https://www.plannedparenthood.org/get-care/health-insurance/about-health-insurance/does-health-insurance-cover-sexual-health-services#:~:text=Testing%20for%20certain%20STDs%20%E2%80%94%20like,and%20if%20you're%20pregnant
13. Considerations for the implementation of point of care tests for syphilis. HHS. June 2024. Accessed August 19, 2024. https://www.hhs.gov/sites/default/files/nscss-considerations-for-the-implementation-of-syphilis-poc-tests.pdf
14. NOWDiagnostics First To Know syphilis test receives FDA de novo marketing authorization for over-the-counter use. News release. NOWDiagnostics; August 16, 2024. Accessed August 19, 2024. https://nowdx.com/blogs/news/nowdiagnostics-first-to-know%C2%AE-syphilis-test-receives-fda-de-novo-marketing-authorization-for-over-the-counter-use
15. Archie A. Pfizer warns of a looming penicillin supply shortage. NPR. June 16, 2023. Accessed August 19, 2024. https://www.npr.org/2023/06/16/1182626821/pfizer-penicillin-shortage#:~:text=Health-,Pfizer%20is%20facing%20a%20penicillin%20shortage%20that%20may%20stretch%20into,rates%20of%20syphilis%20since%202000
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
May 17th 2025Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Specialty Drug Users to Gain Relief Under Medicare Reforms
May 16th 2025A new analysis looked at estimated out-of-pocket costs for etanercept, ustekinumab, and ibrutinib, specialty drugs that often represent a significant cost burden for Medicare Part D beneficiaries and which were selected for 2026 drug price negotiation under the Inflation Reduction Act.
Read More
RFK Jr Claims HHS Has Not Fired Working Scientists, Canceled Lifesaving Research
May 15th 2025Robert F. Kennedy Jr’s congressional hearing featured numerous statements from the secretary of HHS, including denouncing claims of cutting down the HHS and the National Institutes of Health.
Read More
Navigation and Clinician Payment Investments Enhance Colorectal Cancer Screening Benefits
May 15th 2025Investing in patient navigation and clinician incentives ensures colorectal cancer screening completion, improves early detection, reduces disparities, achieves cost savings, and advances population health for all stakeholders.
Read More
